| 0.3214 0 (0.03%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.48  |
1-year : | 0.57 |
| Resists | First : | 0.41 |
Second : | 0.49 |
| Pivot price | 0.37 |
|||
| Supports | First : | 0.29 | Second : | 0.24 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.39 |
| MA(100) : | 0.4 |
MA(250) : | 0.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.9  |
D(3) : | 11.1 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 3 | Low : | 0.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TBIO ] has closed above bottom band by 22.9%. Bollinger Bands are 17.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.34 | 0.34 - 0.34 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.32 - 0.32 | 0.32 - 0.32 |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Thu, 18 Apr 2024
Telesis Bio stock slips amid new CEO (NASDAQ:TBIO) - Seeking Alpha
Thu, 28 Mar 2024
Telesis Bio: Q4 Earnings Snapshot - Houston Chronicle
Mon, 26 Feb 2024
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results | GlobeNewswire by notified - NTB Kommunikasjon
Mon, 26 Feb 2024
Telesis Bio reports record Q4 BioXp kit sales, margin growth - Investing.com
Fri, 23 Feb 2024
Is Telesis Bio Inc (TBIO) a Stock to Watch After Gaining 78.13% This Week? - InvestorsObserver
Fri, 23 Feb 2024
Why Is Telesis Bio (TBIO) Stock Up 29% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 37.3 (%) |
| Held by Institutions | 37 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 342 (K) |
| EPS | -1.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -173.5 % |
| Operating Margin | -87.4 % |
| Return on Assets (ttm) | -29 % |
| Return on Equity (ttm) | -125.5 % |
| Qtrly Rev. Growth | -26.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.91 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.2 |
| PEG Ratio | 0 |
| Price to Book value | 32.13 |
| Price to Sales | 0.35 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|